Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

HIV Transmission Safely Reduced In Babies, Mothers By ART Therapy
Giving daily antiretroviral syrup to breastfeeding infants or treating their HIV-infected mothers with highly active antiretroviral drugs is safe and effective in preventing mother-to-child HIV transmission through breast milk, a study led by University of North Carolina at Chapel Hill investigators has found.
generic viagra online
GenWay Biotech Obtains CLIA Certification
GenWay Biotech, Inc., a US-based diagnostic company has become CLIA certified and received a California lab license. Their license currently permits the testing of immunological biomarkers. This is a very important step in the direction of commercialization of the novel innovative diagnostic tests currently being developed at GenWay. In upcoming weeks, GenWay will add new cancer biomarker tests to their portfolio as well as several infectious diseases such as sexual transmitted diseases. GenWay is seeking to obtain CAP accreditation by the end of the year.
News of the day
Taro Receives FDA Approval For Sulfacetamide Sodium Topical Suspension ANDA
Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," Pink Sheets: TAROF) reported that its Canadian manufacturing site has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Sulfacetamide Sodium Topical Suspension USP, 10% (lotion) ("sulfacetamide sodium lotion").
Mental Health

China Aoxing Pharmaceutical Company Announces Completion Of Registration Trial Of Its Leading Narcotic Drug For The Treatment Of Cough

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and marketing of narcotic and pain-management products, announced that it has completed the registration trial with Codeine Phosphate, a compound oral solution for the treatment of acute moderate to severe cough. Top-line results from this trial are expected to be announced by the end of the third quarter of 2009. Under the regulation of China State Food and Drug Administration ("SFDA"), this drug is designated as a Class III New Medicine, or the first drug to be launched in China while already selling in other regulated territories. As a result, the product is expected to receive at least three-year market exclusivity protection after marketing clearance by the China SFDA. Assuming positive clinical results and timely regulatory approval, the company expects to launch this product in China in 2010. This registration trial is a randomized, multi-center, double-blind, positive-controlled study designed to evaluate the efficacy of a compound oral solution of codeine phosphate in 215 patient subjects with acute moderate to severe cough. "We are pleased to report the successful completion of this study, which has demonstrated excellent safety and efficacy among a significant number of patients," said Liying Yang, Vice President of Research of China Aoxing. "As we continue our analysis of the data collected in this study, we look forward to presenting the top-line results by the end of the third quarter of 2009." The prevalence rate of cough condition is approximately at 15% in China. It is estimated that over 50 million Chinese patients are seeking cough treatment, mainly caused by respiratory disorders. The market size of pharmaceutical product to address cough condition is estimated at approximately $2 billion per year with an annual growth rate of over 10% in China. China Aoxing Pharmaceutical Company, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009